TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. Age 18-65 years~3. Diagnosis of schizophrenia or schizoaffective disorder, depressed type~4. Stable dose of antipsychotic for at least 4 weeks.~5. Able to provide informed consent~6. Able to complete a cognitive battery~Exclusion Criteria:~1. Current treatment with clozapine~2. Dementia~3. Seizure disorder~4. Unstable medical illness~5. Active substance abuse~6. Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- D-cycloserine (Type: EXPERIMENTAL): 50 mg d-cycloserine
- Placebo (Type: PLACEBO_COMPARATOR): 50 mg placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Peritubal Analgesic Infiltration in Postoperative Pain Following Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years of age~* body mass index \<35,~* renal stone size \>2.0 cm.~Exclusion Criteria:~* patients having supra-costal puncture.~* excessive intraoperative bleeding.~* renal stones requiring more than a single puncture.~* surgical procedure extending more than 3 hours.~* urinary tract infection.~* severe cardiopulmonary disease.~* abnormal renal function tests.~* allergy to local anesthetics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- study group :infiltration with 0.25% bupivacaine post-op (Type: ACTIVE_COMPARATOR): At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
- control group , no anesthesia infiltration post-op (Type: NO_INTERVENTION): control group: no anesthesia infiltration had been given post opertatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female Chinese subjects~* Age between 18 to 55 years (both inclusive) at the time of signing informed consent~* Body mass index (BMI) between 20 and 24.9 kg/sqm (both inclusive)~* Body weight greater than or equal to 54.0 kg~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential not using an adequate contraceptive method throughout the trial including follow-up period. Adequate contraceptive measures are sterilisation, intrauterine device (IUD), oral contraceptives or barrier methods~* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases~* Use of prescription or non-prescription systemic products (including routine or non-routine vitamins or herbal products) or topical medicinal products (except paracetamol and oral contraceptives) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to Visit 2 (randomisation)~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2~* History of pancreatitis (acute or chronic)~* Calcitonin greater than or equal to 50 ng/L~* Blood donation, surgery or trauma with significant blood loss (400 mL) within the last 12 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
- Semaglutide 0.5 mg placebo (Type: PLACEBO_COMPARATOR): Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
- Semaglutide 1.0 mg placebo (Type: PLACEBO_COMPARATOR): Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Scheduled for elective PNL operation in general anaesthesia with propofol and remifentanil.~Received oral and written information about the trial Signed the informed consent American Society of Anesthesiologists (ASA) classification 1-3~Exclusion Criteria:~Cannot cooperate Does not speak or understand Danish Allergy towards drugs used in the trial Large daily consumption of opioids Known alcohol or drug abuse Difficulty or inability to visualize the relevant muscular or fascial structures necessary to perform the USG-TQL block Pregnancy~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine TQL block (Type: ACTIVE_COMPARATOR): Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
- Placebo TQL block (Type: PLACEBO_COMPARATOR): Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Sub-Saharan Africa Regional Partnership for Mental Health Capacity Building

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet the following eligibility criteria will be invited to participate:~* Ages 18-65 years (antidepressant treatment considerations differ for those \<18 or \>65 years, and these age groups are expected to be very rare in the target clinics),~* Current or new patient receiving care for either hypertension or diabetes from a participating NCD clinic~* Elevated depressive symptoms (PHQ-9 score ≥5)~Exclusion Criteria:~Patients will be excluded if they have~* a history of bipolar or psychotic disorder, or show emergent threat of self-harm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Basic implementation package (Type: ACTIVE_COMPARATOR): Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
- Enhanced implementation package (Type: EXPERIMENTAL): Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.~2. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening.~Exclusion Criteria:~1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.~2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.~3. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Q203 (Type: EXPERIMENTAL): Q203 tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically or cytologically confirmed relapsed or chemotherapy/immunotherapy-resistant mantle cell lymphoma~  * No more than 3 lines of prior systemic treatment~* At least one measurable lesion ≥ 15 mm in its greatest transverse diameter by CT scan~Exclusion criteria:~* Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningosis)~* Newly diagnosed mantle cell lymphoma~* Patients suitable for intensive treatment (e.g., hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone with high-dose methotrexate and cytarabine \[HyperCVAD\])~PATIENT CHARACTERISTICS:~Inclusion criteria:~* WHO performance status ≤ 2~* Creatinine clearance ≥ 30mL/min~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2 times ULN~* AST and ALT ≤ 2 times ULN~* Neutrophils ≥ 1,500/mm³ (≥ 1,000/mm³ with marrow infiltration)~* Thrombocytes ≥ 100,000/mm³ (≥ 75,000/mm³ in case of bone marrow infiltration)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after study participation~Exclusion criteria:~* Prior or concurrent hematological malignancies~  * Patients with prior solid organ tumors that required no treatment over the last 5 years and are currently free of disease are eligible~* Cardiovascular disease including any of the following:~  * NYHA class III or IV congestive heart failure~ * Unstable angina pectoris~ * Significant arrhythmia or arrhythmia requiring chronic treatment~ * Myocardial infarction in the last 3 months~* Serious underlying medical condition which could impair the ability of the patient to participate in the trial including any of the following:~  * Uncontrolled diabetes mellitus~ * Gastric ulcers~ * Active autoimmune disease~ * Ongoing infection (e.g., HIV or hepatitis)~PRIOR CONCURRENT THERAPY:~Exclusion criteria:~* Prior radiation where the indicator lesion(s) are in the irradiated field~* Prior organ transplantation~* Participation in another clinical trial within 30 days prior to study entry~* Concurrent anticancer drugs/treatments or experimental medications~* Other concurrent investigational therapy~* Other concurrent chemotherapy, immunotherapy, or radiotherapy (including palliative radiotherapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C infection, diagnosed by positive anti-HCV antibodies and detected HCV RNA at screening~2. HCV infection of sub-GT1b confirmed by genotypic testing at screening.~3. HCV viral load =1,000 IU/mL at randomisation.~4. Patients who have never been previously treated with any other HCV treatment regimen.~Exclusion criteria:~1. HCV infection of mixed GT (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening.~2. HCV infection of sub-GT1a, mixed GT1a/1b, or undefined GT1.~3. Liver disease due to causes other than chronic HCV infection.~4. HIV infection.~5. Hepatitis B virus infection based on presence of HBs-Ag.~6. Confirmed or suspected active malignancy or history of malignancy within the last 5 years prior to screening.~7. History of illicit drug abuse other than cannabis or chronic alcohol abuse within 12 months prior to randomisation.~8. Subject is not willing to comply with the precautionary measures to prevent photosensitivity (avoid excessive sun exposure and use sun block on a daily basis).~9. Decompensated liver disease, or history of decompensated liver disease.~10. Clinical evidence of unstable cardiovascular disease which may further decompensate due to anemia.~11. Red blood cell disorders.~12. Body weight \<40 kg or \>125 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Randomised 24-week arm (Type: EXPERIMENTAL): BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
- Randomised 16-week arm (Type: EXPERIMENTAL): BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
- Allocated 24-week arm (Type: EXPERIMENTAL): BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-cirrhotic treatment-naïve participants~* FIB-4 \< 3.25~* albumin \> 3.5~* total bilirubin \< 1.2 mg/dl~* international normalized ratio (INR) \< 1.2~* platelet count \> 150,000 mm3.~* experienced participants who had previously failed treatment with peg-IFN-α-/RBV, SOF/peg-IFN-α +RBV, or SOF/SMV~* Naïve cirrhotic participants were confirmed by ultrasonographic features of cirrhosis~Exclusion Criteria:~* liver disease of non-HCV etiology~* hepatitis B or human immune-deficiency virus (HIV) infection~* poorly controlled diabetic (HbA1C \> 9) participants~* hepatocellular carcinoma~* a history of extra-hepatic malignancy within 5 years prior to the study~* pregnant or breast feeding~* renal disease; serum creatinine \> 2.5 mg/dl or eGFR \< 30 ml/min~* evidence of hepatic decompensation; INR \> 1.7, serum albumin \< 2.8 g/dl, total bilirubin \> 3 mg/dl~* blood picture abnormalities such as anemia (hemoglobin concentration of 10 g/dl or less) and thrombocytopenia (platelet count \< 50,000 cells/mm3)~* major severe illnesses such as congestive heart failure and respiratory failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF/DCV (Type: ACTIVE_COMPARATOR): Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients
- SOF/DCV/RBV + Cirrhosis (Type: ACTIVE_COMPARATOR): This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
- SOF/DCV/RBV + Non-Cirrhosis (Type: ACTIVE_COMPARATOR): This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic constipation (defined as at least 3 months of less than 2 bowel movements (BMs) per week and/or one of the following symptoms : hard stool, painful defecation, encopresis)~* Constipation previously treated by dietary advice (high fiber diet) for at least two weeks without efficacy~Exclusion Criteria:~* Organic bowel diseases~* Suspected GI obstruction~* History of GI surgery

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets criteria for 1 of the 4 defined study cohorts~* TNBC, defined as estrogen receptor (ER) and progesterone receptor (PR) negative (\< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization \[FISH\] negative)~* Metastatic disease or locally-advanced disease not amenable to curative intent treatment~* Adequate hepatic, renal, cardiac, and hematologic function~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.4.0~Key Exclusion Criteria:~* Known brain metastases or central nervous system (CNS) cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 mo~* Unable to receive oral medications~* Known hypersensitivity to Cremophor®-based agents~* Major surgery within 28 days of Cycle 1 Day 1

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - African ancestry, 3rd line+ (Type: EXPERIMENTAL): Intervention = Paclitaxel- CB-839 (Pac-CB) combination~1. Participants must self-identify as African ancestry (includes African American).~2. At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~   * Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~  * Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo.
- Cohort 2 - African ancestry, 1st line (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants must self-identify as African ancestry (includes African American).~2. No prior systemic therapy for advanced or metastatic disease.~   * Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was \> 12 mo.
- Cohort 3 - Non-African ancestry, 3rd line+ (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 1.
- Cohort 4 - Non-African ancestry, 1st line (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete